- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05392699
ABOD2011 in pazienti con tumori solidi avanzati progrediti dopo terapia sistemica standard
Uno studio di aumento della dose in cieco per valutare la sicurezza, la tollerabilità e l'efficacia preliminare di ABOD2011 in pazienti con tumori solidi avanzati progrediti dopo terapia sistemica standard
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.
The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Beijing, Cina
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 18 years and older.
- Understand and voluntarily sign the informed consent form (ICF).
- Histopathologically confirmed recurrent or metastatic solid tumors.
- Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
- Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
- At least one superficial or deep lesion for intratumoral administration and biopsy.
- Sufficient organ functions.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Weight > 30 kg.
- Expected survival longer than 12 weeks.
- Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.
Exclusion Criteria:
- Any systemic anti-tumor therapy, within 28 days prior to the first dose.
- Radiotherapy within 14 days prior to first dose.
- Use of immunosuppressants.
- Major surgery within 28 days.
- Inadequately controlled diseases.
- Active autoimmune and inflammatory diseases.
- Clinically symptomatic central nervous system tumors or metastases.
- Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
- Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
- Active infections.
- Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-single dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only |
|
Sperimentale: Human single chain IL-12 mRNA-multiple dose
Human single chain IL-12 mRNA-multiple dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Lasso di tempo: From first dose to Day 28
|
Number of Participants Experiencing dose-limiting toxicities (DLTs) |
From first dose to Day 28
|
|
Number of Participants Experiencing Adverse Events (AEs)
Lasso di tempo: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
|
Number of Participants Experiencing Severe Adverse Events (SAEs)
Lasso di tempo: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Number of Participants Experiencing Severe Adverse Events (SAEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Response Rate (ORR)
Lasso di tempo: Up to 36 months
|
Overall Response Rate (ORR) |
Up to 36 months
|
|
Disease Control Rate(DCR)
Lasso di tempo: Up to 36 months
|
Disease Control Rate(DCR) |
Up to 36 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 36 months
|
Duration of Response (DOR) |
Up to 36 months
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to 36 months
|
Progression-Free Survival (PFS) |
Up to 36 months
|
|
Overall Survival
Lasso di tempo: Up to 36 months
|
Overall Survival |
Up to 36 months
|
|
Maximum observed concentration (Cmax) of ABOD2011
Lasso di tempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of ABOD2011
Lasso di tempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Area under the concentration-time curve (AUC) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Maximum observed concentration (Cmax) of IL-12
Lasso di tempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of IL-12
Lasso di tempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Area under the concentration-time curve (AUC) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
|
Plasma concentration of IFN gamma
Lasso di tempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Plasma concentration of IFN gamma |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- ABOD2011-001
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .